Heart Failure, Type 2 Diabetes, Atrial Fibrillation
Conditions
Brief summary
This initiative supports a quality improvement effort evaluating the use of strategies (including technology-based decision support, referral to a virtual GDMT team, and general educational tools/resources for clinicians and patients) to improve use of guideline-directed therapeutics known to lower cardiovascular (CV) events among patients with cardiovascular diseases of heart failure, atrial fibrillation and type 2 diabetes (T2D)/ASCVD with a specific focus on underserved populations and those with a history of health care disparities.
Detailed description
TRANSFORM3 is a Quality Improvement initiative conducted in parallel to the current TRANSFORM CVRiD study and aligned with its goals of using a real-world population study to enable the American College of Cardiology Foundation (ACCF) to better identify impactful ways to improve guideline directed medical therapy for patients. TRANSFORM3 is focused on improving GDMT use in underserved patients and patients with a history of health care disparities who have one or more of the following: heart failure, atrial fibrillation, and ASCVD/Type 2 diabetes. There is a significant disconnect between increasing availability of effective and safe therapeutics that significantly reduce CV event risk in patients with Heart Failure, T2D and ASCVD, and Atrial Fibrillation-and clear guideline recommendations endorsing these therapies-but very low adoption in clinical practice with the majority of eligible patients that are most likely to benefit from these therapies not receiving them. A high proportion of patients have more than one of these conditions further reducing the chances of receiving optimal guideline directed medical therapy and avoiding the CV events they are designed to prevent.
Interventions
BEHAVIORALDecision Support
Prompts will be provided to clinicians signaling gaps in guideline-directed care
BEHAVIORALReferral
Patients will be referred to an interdisciplinary, expert guideline-directed medical therapy team
Sponsors
American College of Cardiology
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Age ≥18 years 2. Personal access to a computer and/or Smartphone for app download 3. Heart Failure (reduced and preserved ejection fraction) AND/OR 4. Atrial Fibrillation with CHA2DS2-VASc score greater than or equal to 2 in men and greater than or equal to 3 in women AND/OR 5. T2D and ASCVD, defined as follows: 1. Known CAD, prior ACS, or coronary artery revascularization 2. Prior TIA/stroke or known carotid or intracerebral atherosclerosis 3. Prior PAD including requiring revascularization
Exclusion criteria
All patients 1. Current or anticipated participation in an interventional clinical trial of a drug/device 2. Currently receiving comfort care or enrolled in hospice 3. Life expectancy \<1 year 4. Pregnancy or active breastfeeding 5. Current or anticipated participation in an interventional clinical trial (other than TRANSFORM3 GDMT) 6. Patients without a clinical encounter within three years of study start date Heart Failure patients: 1. History of or plan for heart transplantation or left ventricular assist de-vice 2. Palliative chronic inotropic therapy 3. NYHA Class 4 heart failure Atrial Fibrillation patients: 1. Current prescription for OAC 2. Reversible cause of atrial fibrillation, such as post-cardiothoracic surgery or thyrotoxicosis 3. History of ischemic stroke in prior 7 days 4. Transient ischemic attack in prior 3 days 5. Platelet count \<70,000/ml 6. Hemoglobin concentration \<8g/dl 7. History of or condition associated with increased bleeding risk, such as hemophilia 8. Major surgical procedure or trauma within 14 days 9. Clinically significant gastrointestinal bleeding within 8 weeks
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adoption of evidence-based CV-risk reduction and disease management therapies for HF, AF, and T2D/ASCVD. This data will be found in the patient's medical record. | 9 months | GDMT baseline to 9 month change in average composite endpoint of receiving the main classes of drugs (50% or higher of target doses for HF) among eligible patients. We're aiming to see a change or increase in guideline-directed care where there was an original gap. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life Outcome-MMA-4 | Study duration up to 1 year. | Difference in patient reported outcomes on Morisky Medication Adherence Scale (MMAS-4) from baseline, 3 and at 9 months. |
| Quality of Life Outcome-KCCQ-12 | Study duration up to 1 year. | Difference in patient-reported outcome/KCCQ-12 scores from baseline to 9 months (applicable to HFrEF and HFpEF study cohorts only). |
| Quality of Life Outcome-PAM | Study duration up to 1 year. | Difference in patient reported outcomes on Patient Activation Measure® (PAM) from baseline, 3 and at 9 months. |
Countries
United States
Contacts
Primary ContactLindsey C Hill
Backup ContactShilpa Patel
Outcome results
None listed